Brought to you by Bulls N’ Bears
Doug Bright
Proteomics International Laboratories has appointed seasoned healthcare and medtech executive David Morris as CEO and managing director to spearhead the commercial rollout of its Promarker diagnostics suite.
Morris steps into the role with a strong track record in the industry, including executive leadership at Cochlear, Nanosonics, Polynovo and Monash IVF.
The company says, in particular, that he brings proven expertise in driving commercial growth, international expansion, product commercialisation and building high-performing teams – skills well-suited to accelerating the company’s Promarker precision diagnostics pipeline across key markets.
His appointment comes hot on the heels of last year’s announcement that the company’s US Reference Laboratory in Irvine, California, has secured accreditation from the College of American Pathologists (CAP).
‘I would also like to acknowledge and thank Richard for his outstanding contribution in establishing Proteomics.’
Proteomics International Laboratories chairman Dr James Williams
The accreditation for testing clinical samples is recognised for its rigorous and robust standards and is widely considered the gold standard for laboratory quality in the United States.
The esteemed accreditation adds to the lab’s existing Clinical Laboratory Improvement Amendments (CLIA) certification and California State Licence, further strengthening the company’s regulatory credentials.
It will also support the commercial rollout of Proteomics’ non-invasive PromarkerEso and PromarkerEndo diagnostic tests for esophageal cancer and endometriosis, respectively.
Proteomics International Laboratories chairman Dr James Williams said: “The Board is delighted to appoint David as CEO. He brings deep commercial expertise in medical technology and a proven ability to translate innovative science into commercial outcomes.”
Morris, who is due to take the top spot on 19 January, will succeed Proteomic’s founder Dr Richard Lipscombe, who is set to retire on 23 February after 25 years of distinguished service that has positioned the company as a leader in innovative precision diagnostics.
With regulatory boxes ticked and strong commercial leadership now in place, Proteomics International appears well-positioned to push its Promarker diagnostics from validation into widespread clinical adoption.
For punters, the story is rapidly shifting from scientific promise to execution, with scale, sales, and market access likely to be key to the next leg of growth.
Is your ASX-listed company doing something interesting? Contact: mattbirney@bullsnbears.com.au
